WASHINGTON, D.C.—Ketchum has won several significant healthcare accounts that will be managed from its Washington office. The new accounts include Montefiore Medical Center, Wyeth Consumer Health’s Robitussin, Celera Genomics and Celera Diagnostics, and Solvay Pharmaceuticals, and involve community relations, media relations, leadership positioning, product launches and marketing, third-party outreach and issues management.
A combined Ketchum Washington and New York team is launching a regional and national image awareness, visibility and leadership positioning campaign for the New York City-based Montefiore Medical Center.
Ketchum Washington is mounting a PR campaign to support the launch of Robitussin CoughGels, an over-the-counter, cough suppressant in a liquid-filled capsule, while also helping Wyeth manage any issues that arise publicly relating to the abuse of dextromethorphan (the active ingredient in Robitussin).
In tandem with Ketchum San Francisco, the Washington office is preparing biotech companies Celera Genomics and Celera Diagnostics to announce the results of several research programs aimed at identifying genetic variations linked to specific diseases.
Finally, Solvay has selected Ketchum as its agency of record to provide global strategic counsel and support for pre-launch and launch activities for its new innovative irritable bowel syndrome treatment. Managed by Ketchum D.C., the global initiative involves Ketchum offices in the United Kingdom, Germany, France, Italy and Canada and focuses on developing strategic messages, product positioning and public relations support in preparation for approval and launch.